BCMA/CD3 Bispecific Antibody Treatment for Newly Diagnosed Amyloidosis
Recruiting now · Phase 2
Conditions studied: Systemic Light Chain Amyloidosis
In brief
This is a prospective, single-arm, single-center clinical study designed to evaluate the efficacy and safety of low-dose BCMA/CD3 bispecific antibody (CM336) in patients newly diagnosed with systemic light chain (AL) amyloidosis.
Key facts
- Study ID
- NCT07151690
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
- People needed
- 21
- Starts
- 2025-09-04
- Expected to finish
- 2027-12-01
- Last updated by the study team
- 2026-07-23
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences — Tianjin, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.